- Do Young Kim, Gabriel Wong, Janet Lee, Myung Hwa Kim, Nathaniel Smith, Rob Blissett, Hyung Joon Kim. Cost-effectiveness of increased screening and treatment of chronic hepatitis C in Korea. Current Medical Research and Opinion 2020;36:993

- Do Young Kim. Estimation of Direct Medical Costs Related to Chronic Hepatitis C: A Rationale for Early Antiviral Therapy. Gut and Liver 2017;11:745

- Laurent Lam, Patrizia Carrieri, Gilles Hejblum, Jonathan Bellet, Marc Bourlière, Fabrice Carrat. Real‐world economic burden of hepatitis C and impact of direct‐acting antivirals in France: A nationwide claims data analysis. Liver International 2024;44:1233

- Kyung-Ah Kim, June Sung Lee. Prevalence, Awareness, and Treatment of Hepatitis C Virus Infection in South Korea: Evidence from the Korea National Health and Nutrition Examination Survey. Gut and Liver 2020;14:644

- Hankil Lee, Beom Kyung Kim. Real‐world clinical features, health‐care utilization, and economic burden in decompensated cirrhosis patients: A national database. J of Gastro and Hepatol 2022;37:2154

- Yong Kyun Won, Kyung Sik Kang, Yuri Sanchez Gonzalez, Homie Razavi, Ellen Dugan, Kwang-Hyub Han, Sang Hoon Ahn, Mi Young Jeon, Do Young Kim, Tatsuo Kanda. A tool to measure the impact of inaction toward elimination of hepatitis C: A case study in Korea. PLoS ONE 2020;15:e0232186

- Hye Won Lee, Hankil Lee, Beom Kyung Kim, Young Chang, Jae Young Jang, Do Young Kim. Cost-effectiveness of chronic hepatitis C screening and treatment. Clin Mol Hepatol 2022;28:164

- T. Joseph Mattingly, Bryan L. Love, Bilal Khokhar. Real World Cost-of-Illness Evidence in Hepatitis C Virus: A systematic review. PharmacoEconomics 2020;38:927

- Kyung‐Ah Kim, Wankyo Chung, Hwa Young Choi, Moran Ki, Eun Sun Jang, Sook‐Hyang Jeong. Cost‐effectiveness and health‐related outcomes of screening for hepatitis C in Korean population. Liver International 2019;39:60
